BIORESTORATIVE THERAPIES, INC. BioRestorative Therapies, Inc. announced that it has selected 10 of its 15 clinical sites for its Phase 2 clinical trial targeting chronic lumbar disc disease. BioRestorative's Phase 2 trial is a double-blind controlled, randomized study to evaluate the safety and preliminary efficacy of a single dose intradiscal injection of BRTX-100. A total of up to 99 eligible patients will be randomized at 15 centers in the United States to receive either the investigational drug (BRTX-100) or control in a 2:1 fashion.
The initial 10 clinical sites for the Phase 2 are located across the United States in the following cities: Greenwood Village, CO, Tyler, TX, Cleveland, OH, Richmond, VA, St. Petersburg, FL, Tampa, FL (2 sites), North Charleston, SC, Winston-Salem, NC, San Diego, CA.
